Danaher announced a definitive agreement to acquire Masimo for approximately $10 billion in cash, expanding Danaher’s footprint in patient monitoring and diagnostics. The deal values Masimo at $180 per share and is positioned as a strategic move to integrate pulse oximetry and perioperative monitoring into Danaher’s diagnostics and acute-care portfolio. Executives said the acquisition aims to deliver scale and broaden Danaher’s hospital offerings amid rising demand for integrated monitoring solutions. The transaction underscores continued consolidation as larger device and diagnostics firms seek vertical integration and richer hospital data streams. Regulatory clearance and integration plans will be watched closely, as the deal could reshape acute-care device supply chains and influence competitive dynamics in monitoring and perioperative technologies.